title: Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
abstract: Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to raise high-density lipoprotein cholesterol (HDL-C) and reduce cardiovascular risk. This review focuses on the highly selective and potent CE TP inhibitor anacetrapib and discusses the available preclinical and clinical information pertaining to it. We also describe strategies to target HDL-C, discuss the mechanism underlying CETP inhibition and its effects on lipid biology, and give an overview of other CETP inhibitors that are currently in development.
authors: Merck Sharp & Dohme Corp., Rahway, New Jersey, USA. david_gutstein@merck.com
authors: D E
authors: DE
authors: Gutstein
authors: R
authors: R
authors: Krishna
authors: D
authors: D
authors: Johns
authors: H K
authors: HK
authors: Surks
authors: H M
authors: HM
authors: Dansky
authors: S
authors: S
authors: Shah
authors: Y B
authors: YB
authors: Mitchel
authors: J
authors: J
authors: Arena
authors: J A
authors: JA
authors: Wagner
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D023303:Oxazolidinones / Q000627:therapeutic use*; D040242:Risk Reduction Behavior
chemical_list: D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D023303:Oxazolidinones; C530884:anacetrapib